Takeda’s Adcetris (brentuximab vedotin) has been given the regulatory go-head in Japan to treat malignant lymphoma.
More specifically, the Japanese Ministry of Health, Labour and Welfare (MHLW) has issued a greenlight for its use in patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma (HL) or Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL).
Read more at: http://www.pharmatimes.com/Article/14-01-18/Takeda_wins_Japanese_OK_for_Adcetris.aspx#ixzz2qwGAi5Qo
